Newsroom

Industry News

11 Nov

Inovio to Present at Upcoming Investor Conferences

Inovio Pharmaceuticals, Inc. (INO) announced today that Dr. J. Joseph Kim, President & CEO, will present a corporate overview at the upcoming Stifel Healthcare Conference, Brean Capital Life Science Conference, and Piper Jaffray Healthcare Conference in New York, NY. Stifel Healthcare Conference November 18, 2014 10:55 AM ET Investor...

Read more

11 Nov

How Social Media Is Altering IR/PR

Social media has become a critical component of any comprehensive investor and public relations program conducted by a publicly traded company. A company without a well-defined and properly implemented social-media program is passing up an opportunity to disseminate its story to the widest possible audience. In essence, capturing a...

Read more

11 Nov

NXT-ID to Close Pre-Orders for Wocket(TM) Smart Wallet; First Wockets to Ship in 2014

General Release to Follow 2015 International CES (Consumer Electronics Show) SHELTON, CT–(Marketwired – Nov 10, 2014) – NXT-ID, Inc. (NASDAQ:NXTD) (NASDAQ: NXTDW) (“NXT-ID” or the “Company”), a biometric authentication company focused on the growing mobile commerce market announces it will close pre-orders at midnight on November 14, 2014 in...

Read more

10 Nov

BioSig Issues Special Letter to Shareholders

BioSig Technologies, Inc. (BSGM) today issued the following Special Letter to Shareholders from its Chief Executive Officer, Gregory D. Cash. Dear Shareholder: BioSig’s recent transition to a publicly traded company was a major milestone for our company. I would like to thank our many long-term shareholders for their support,...

Read more

7 Nov

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73

 Neuronetrix has been selected by Anavex Life Sciences Corp. (AVXL) to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer’s disease.  Neuronetrix will be utilizing their COGNISION™ System to measure and analyze cognitive biomarkers in study participants. The ANAVEX 2-73 study...

Read more

6 Nov

Anavex to Present at SeeThruEquity Investor Conference in New York City

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, will be featured at theSeeThruEquity Fall Microcap Investor Conference in New York City. Christopher U....

Read more

6 Nov

BioSig Begins Trading with Ticker Symbol BSGM

BioSig Technologies (BSGM), a company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of cardiac recordings in the $3 billion electrophysiology (EP) marketplace(1), today announced it has received notice from the Depository Trust Company (DTC) that...

Read more

6 Nov

Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin

AC5(TM) Quickly Stopped Bleeding in Animals Prescribed Antiplatelet Medications Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostat Device ™, announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5™ in animals that...

Read more

Page 249 of 276« First...102030...247248249250251...260270...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address